| 78.2 8.32 (11.91%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 92.09  |
1-year : | 107.56 |
| Resists | First : | 78.84 |
Second : | 92.09 |
| Pivot price | 66.48 |
|||
| Supports | First : | 65.01 |
Second : | 56.47 |
| MAs | MA(5) : | 69.39 |
MA(20) : | 65.02 |
| MA(100) : | 77.7 |
MA(250) : | 67.05 |
|
| MACD | MACD : | -0.8 |
Signal : | -2.5 |
| %K %D | K(14,3) : | 74.3 |
D(3) : | 64.5 |
| RSI | RSI(14): 62.3 |
|||
| 52-week | High : | 123.75 | Low : | 24 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DRUG ] has closed Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 78.92 - 79.23 | 79.23 - 79.58 |
| Low: | 69.62 - 69.92 | 69.92 - 70.27 |
| Close: | 77.59 - 78.12 | 78.12 - 78.72 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Wed, 08 Jul 2026
Bright Minds Biosciences Inc Company Profile & Introduction - Moomoo
Thu, 02 Jul 2026
Ian McDonald reports 13.6% Bright Minds (DRUG) ownership stake - Stock Titan
Tue, 30 Jun 2026
We're Not Very Worried About Bright Minds Biosciences' (CSE:DRUG) Cash Burn Rate - simplywall.st
Sun, 28 Jun 2026
Bright Minds Biosciences Inc (DRUG) Stock Forum and Discussion - Moomoo
Fri, 26 Jun 2026
Bright Minds Biosciences Inc. Actuals & Estimates (CSE:DRUG) - TradingView
Sun, 21 Jun 2026
DRUG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 92.8 (%) |
| Shares Short | 818 (K) |
| Shares Short P.Month | 756 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.5 % |
| Return on Equity (ttm) | -15.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -32.59 |
| PEG Ratio | 0 |
| Price to Book value | 3.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -38.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|